

**Guided Questionnaire for Patients reporting  
Mycophenolate sodium (Myfortic®)  
Exposure during Pregnancy**

<b>Product Name: Myfortic</b>			
<b>To be completed by Novartis :</b>			
Global AER #:		Local Case ID:	

**IMPORTANT**

**If you have not already contacted your doctor regarding the reported pregnancy  
please do so immediately**

Following your recent report to Novartis regarding your pregnancy or your partner's pregnancy, we would like to ask you to complete this short tick-box questionnaire. Answering this questionnaire will not affect the treatment you receive from your doctor. The information you provide is confidential and nothing that identifies you will be recorded. The information you supply will help us to ensure that Myfortic (mycophenolate sodium) is used as safely as possible. Please answer all questions and send the questionnaire back to:

*Novartis Pharma Services Inc., Representative Office Malta, PO Box 4, Marsa, MRS 1000.*

By returning this questionnaire you are agreeing that Novartis can enter the anonymous information you provide onto a computer database. Thank you for taking the time to complete this questionnaire.

1. Information about you		
Are you male or female? <input type="checkbox"/> Male <input type="checkbox"/> Female	Was this pregnancy planned? <input type="checkbox"/> Yes <input type="checkbox"/> No	When did you start therapy with Myfortic ? <input type="checkbox"/> Date: _____ <input type="checkbox"/> Do not remember

2. Information received before starting taking Myfortic(mycophenolate sodium)			
a. Did you receive the Myfortic <i>Guide for Patients</i> about risks to the unborn baby?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Do not remember
b. <b>Female patients only:</b> were you told not to become pregnant and to use effective contraception when taking Myfortic and for 6 weeks after stopping Myfortic?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Do not remember

2. Information received before starting taking Myfortic(mycophenolate sodium)			
c. <b>Male patients only:</b> were you told not to father a child and to use effective contraception when taking Myfortic and for 90 days after stopping Myfortic?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Do not remember
d. Did you receive information about what contraception you should use?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Do not remember
e. If you answered yes to questions a, b, c or d, who provided the information? (please check/tick all that apply)	<input type="checkbox"/> Doctor who prescribed Myfortic <input type="checkbox"/> Gynaecologist <input type="checkbox"/> Contraceptive counsellor, family planning advisor, health educator, nurse, pharmacist <input type="checkbox"/> Other (please specify) <hr/> <input type="checkbox"/> Do not remember		

3. Information about pregnancy testing and contraception (birth control)	
a. <b>Female patients only:</b> did you have negative pregnancy tests before you started taking Myfortic?	<input type="checkbox"/> Yes, one negative test <input type="checkbox"/> Yes, two negative tests <input type="checkbox"/> No <input type="checkbox"/> Do not remember
b. Did you use two forms of contraception when you were taking Myfortic and for 6 weeks (for female patients) or 90 days (for male patients) after stopping Myfortic?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Do not remember
c. If you used contraception, what types of contraception did you use? Please check/tick all that apply	<input type="checkbox"/> Intrauterine device (IUD) or coil <input type="checkbox"/> Hormonal (Progestin) IUD <input type="checkbox"/> Hormones (birth control/contraceptive pills, hormonal patches, shots or implants) <input type="checkbox"/> Sterilization (tubal sterilization, hysterectomy, vasectomy) <input type="checkbox"/> Condom with spermicide <input type="checkbox"/> Condom without spermicide <input type="checkbox"/> Diaphragm with spermicide <input type="checkbox"/> Diaphragm without spermicide

3. Information about pregnancy testing and contraception (birth control)	
	<input type="checkbox"/> Abstinence <input type="checkbox"/> Cervical cap or shield <input type="checkbox"/> Sponge <input type="checkbox"/> Withdrawal <input type="checkbox"/> Other (please specify) _____

4. Information on sexual intercourse without effective contraception (birth control)	
a. Did you or your partner have sexual intercourse without effective contraception <u>at any time during or within 6 weeks (for female patients) or 90 days (for male patients) after the use of Myfortic?</u>	<input type="checkbox"/> Yes – please respond also to question 5  <input type="checkbox"/> No – please ignore question 5

5. Reason contraception (birth control) was not used or was not effective	
a. Please check/tick all that apply	<input type="checkbox"/> Forgot to use contraception <input type="checkbox"/> Contraception failed (for example condom split/broke) <input type="checkbox"/> Stopped using contraception. Please explain why: _____ _____ <input type="checkbox"/> Did not know contraception should be used <input type="checkbox"/> Other (please specify) _____

**Thank you for completing this questionnaire.**

Completed by:			
Initials only:		Date:	

Suspected adverse reactions and medication errors associated with the use of Myfortic should be reported to: Medicines Authority Post-licensing Directorate, 203, Level 3, Rue D'Argens, Gzira GZR 1368, MALTA or at: [www.medicinesauthority.gov.mt/adrportal](http://www.medicinesauthority.gov.mt/adrportal)

Alternatively at: Novartis Pharma Services Inc. Representative Office Malta by phone on 21222872  
 Marketing Authorisation Holder: Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Camberley, Surrey GU16 7SR, United Kingdom.

MYF PQ 02/16 MT